About Us
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world.
A Proven Track Record of Global Impact
Organizations
Served across 90 countries and
6 continents
Publications in SCI journals
(As of December 2024)
Cumulative impact factor
Samples sequenced annually
Patents
Software copyrights
Leadership
Company founder, Dr. Ruiqiang Li
Dr. Li Ruiqiang is the founder and CEO of Novogene, one of the world’s leading providers of next-generation sequencing (NGS) services. A globally recognized expert in genomics and bioinformatics, Dr. Li has authored over 100 scientific publications and holds 35 patent applications. He is best known for developing SOAP (Short Oligonucleotide Analysis Package), a groundbreaking software for ultra-fast sequence mapping, variation detection, and de novo genome assembly. Under his leadership, Novogene has become a trusted genomics partner, sequencing over 3 million samples annually to empower researchers worldwide in advancing genomics and improving lives.
Milestones
-
Advanced Single-Cell RNA Sequencing with Chromium GEM-X and Single Cell Gene Expression v4 Kit, as a 10X Genomics Certified Service Provider.
Launched PacBio Isoform Sequencing with Kinnex™ Full-Length RNA Kit, achieving 16X more HiFi reads with PacBio Revio technology.
Unveiled Pre-made Library Swift Sequencing with 4-day turnaround using NovaSeq™
Introduced Nanopore Ultra-Long DNA Sequencing, with N50 over 50kb and reads extending beyond 4 Mb.
2024 -
Novogene opens lab and omics core in Germany and Japan respectively, continuing its global localization strategy and further enhancing regional service capabilities
Global deployment of new technology platforms to consolidate the leading position
2023 -
The self-developed Falcon II platform is deployed globally
2022
-
Launched Falcon, our world-leading intelligent NGS delivery platform, to significantly improve the efficiency, reliability and quality of production.
2020 -
Established Novogene Netherlands B.V. and Novogene Japan k.k.
2019 -
Received CFDA Approval for NovoFocus NSCLC CDx Test.
Obtained CLIA certification for the UC Davis Sequencing Center.
Established the Cambridge Sequencing Center.
2018
-
Obtained the first CAP Certification for an NGS Lab – the first in Mainland China.
Introduced mass spectrometry platform and expanded our multiomics service capacity.
2017 -
Established Novogene (HK) Company Ltd. and started to expand global business.
2013 -
Opened first sequencing center in the US at the University of California, Davis. This started the glocalization process.
2016
-
Built the first sequencing platform to deliver end-to-end services.
2012
